1. 105PDetection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292. (23rd October 2018) Authors: Besse, B; Subbiah, V; Drilon, A; Shah, M; Wirth, L J; Bauer, T M; Velcheti, V; Lakhani, N; Boni, V; Solomon, B J; Johnson, M; Park, K; Patel, J; Cabanillas, M E; Sherman, E; Zhu, E; Gordon, K; Ebata, K; Tuch, B; Oxnard, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 80PTRK wild-type and fusion protein expression in solid tumors: Characterization by immunohistochemistry and in situ hybridization. (16th September 2018) Authors: Feng, J; Ebata, K; Hansen, F; Kivi, L; Kriegshauser, C; Morosini, D; Shen, T-S; Sireci, A N; Thorne-Nuzzo, P; Tuch, B Journal: Annals of oncology Issue: Volume 29:Number 6(2018)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Selective RET kinase inhibition for patients with RET-altered cancers. (18th April 2018) Authors: Subbiah, V; Velcheti, V; Tuch, B B; Ebata, K; Busaidy, N L; Cabanillas, M E; Wirth, L J; Stock, S; Smith, S; Lauriault, V; Corsi-Travali, S; Henry, D; Burkard, M; Hamor, R; Bouhana, K; Winski, S; Wallace, R D; Hartley, D; Rhodes, S; Reddy, M Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1869 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗